text:
Contact Us
Enter Your Search:
Search tips
Search criteria
Journal titles
Results 1-25 (579251)
« Previous
Go to page number:
Next »
Clipboard (0)
Related Articles
L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Ralph, Anna P.
Waramori, Govert
Pontororing, Gysje J.
Kenangalem, Enny
Wiguna, Andri
Tjitra, Emiliana
Lolong, Dina B.
Yeo, Tsin W.
Chatfield, Mark D.
Soemanto, Retno K.
Bastian, Ivan
Lumb, Richard
Maguire, Graeme P.
Eisman, John
Price, Ric N.
Morris, Peter S.
Kelly, Paul M.
Anstey, Nicholas M.
PLoS ONE
Vitamin D (vitD) and L-arginine have important antimycobacterial effects in humans. Adjunctive therapy with these agents has the potential to improve outcomes in active tuberculosis (TB).
In a 4-arm randomised, double-blind, placebo-controlled factorial trial in adults with smear-positive pulmonary tuberculosis (PTB) in Timika, Indonesia, we tested the effect of oral adjunctive vitD 50,000 IU 4-weekly or matching placebo, and L-arginine 6.0 g daily or matching placebo, for 8 weeks, on proportions of participants with negative 4-week sputum culture, and on an 8-week clinical score (weight, FEV1, cough, sputum, haemoptysis). All participants with available endpoints were included in analyses according to the study arm to which they were originally assigned. Adults with new smear-positive PTB were eligible. The trial was registered at ClinicalTrials.gov NCT00677339.
200 participants were enrolled, less than the intended sample size: 50 received L-arginine + active vitD, 49 received L-arginine + placebo vit D, 51 received placebo L-arginine + active vitD and 50 received placebo L-arginine + placebo vitD. According to the factorial model, 99 people received arginine, 101 placebo arginine, 101 vitamin D, 99 placebo vitamin D. Results for the primary endpoints were available in 155 (4-week culture) and 167 (clinical score) participants. Sputum culture conversion was achieved by week 4 in 48/76 (63%) participants in the active L-arginine versus 48/79 (61%) in placebo L-arginine arms (risk difference −3%, 95% CI −19 to 13%), and in 44/75 (59%) in the active vitD versus 52/80 (65%) in the placebo vitD arms (risk difference 7%, 95% CI −9 to 22%). The mean clinical outcome score also did not differ between study arms. There were no effects of the interventions on adverse event rates including hypercalcaemia, or other secondary outcomes.
Neither vitD nor L-arginine supplementation, at the doses administered and with the power attained, affected TB outcomes.
ClinicalTrials.gov. Registry number: NCT00677339
Related Articles
Calcium and vitamin D intakes in children: a randomized controlled trial
Cosenza, Linda
Pezzella, Vincenza
Nocerino, Rita
Di Costanzo, Margherita
Coruzzo, Anna
Passariello, Annalisa
Leone, Ludovica
Savoia, Marcella
Del Puente, Antonio
Esposito, Antonella
Terrin, Gianluca
Berni Canani, Roberto
BMC Pediatrics
Calcium (Ca2+) and vitamin D (VitD) play an important role in child health. We evaluated the daily intake of Ca2+ and VitD in healthy children. Moreover, we demonstrate the efficacy of Ca2+ and VitD supplementation.
Daily Ca2 + and VitD intake was evaluated in consecutive healthy children through a validated questionnaire. Subjects with <70% of dietary reference intakes (DRIs) of Ca2+ and VitD were invited to participate in a prospective randomized trial with 2 groups of nutritional intervention: Group 1, dietary counseling aiming to optimize daily Ca2+ and VitD intake plus administration of a commercially available Ca2 + and VitD supplementation product; Group 2, dietary counseling alone. At the enrollment (T0) and after 4 months (T1) serum 25(OH) Vitamin D levels were assessed.
We evaluated 150 healthy children (male 50%, mean age 10 years); at baseline a low VitD intake was observed in all subjects (median 0.79 μg/die, IQR 1.78; range 0.01-5.02); this condition was associated with Ca2+ intake <70% of the DRIs in 82 subjects (55%). At baseline serum 25(OH)D levels were low (<30 ng/ml) in all study subjects and after 4 months of nutritional intervention, a normalization of serum 25(OH)D levels (≥30 ng/ml) was observed in all children in Group 1 and in only one subject in Group 2 [Group 1: T1 33.8 ng/ml (IQR 2.5) vs Group 2: T1 24.5 ng/ml (IQR 5.2), p <0.001].
Adequate Ca2+ and VitD intakes are difficult to obtain through dietary counseling alone in pediatric subjects. Oral supplementation with of Ca2+ and VitD is a reliable strategy to prevent this condition.
Trial registration
The study was registered in Clinical Trials Protocol Registration System (ID number: NCT01638494).
25-hydroxyvitamin D; Dietary counseling; Pediatrics; Ca2+ intake; VitD intake; Bone metabolism; Nutritional intervention; Vitamin D supplement; Vitamin D deficiency
Related Articles
Prognostic Role of Vitamin D Status and Efficacy of Vitamin D Supplementation in Cancer Patients: A Systematic Review
Buttigliero, Consuelo
Monagheddu, Chiara
Petroni, Paola
Saini, Andrea
Dogliotti, Luigi
Ciccone, Giovannino
Berruti, Alfredo
The Oncologist
Whether or not hypovitaminosis D can influence the prognosis of cancer patients and whether or not vitamin D supplementation improves outcome were examined through a literature review. It was concluded that the currently available evidence is insufficient to recommend vitamin D supplementation in cancer patients in clinical practice.
Whether or not hypovitaminosis D can influence the prognosis of cancer patients and whether or not vitamin D (vitD) supplementation improves outcome remain controversial.
Studies evaluating the prognostic role of vitD and vitD receptor (VDR) in cancer patients and trials evaluating the efficacy of vitD administration on patient outcome were identified by a search of MEDLINE, EMBASE, ISI Web of Knowledge, and the Cochrane Library through June 2010.
Twenty-five studies were included. A negative prognostic role for low serum vitD level was observed in five cohort studies including patients with breast cancer (one study), colon cancer (two studies), prostate cancer (one study), and melanoma (one study), but not in two studies on non-small cell lung cancer and one study on breast cancer. Three of four studies showed that VDR+ tumors carry a better prognosis than VDR− tumors, whereas VDR polymorphisms were significantly associated with prognosis in five of 10 studies. A significant interaction between serum vitD level and VDR polymorphism was observed in one study. Three randomized trials involving advanced prostate cancer patients explored the prognostic role of vitD supplementation. A meta-analysis of these trials showed no effect on survival (pooled risk ratio, 1.07; 95% confidence interval, CI, 0.93–1.23), with strong heterogeneity among studies.
Hypovitaminosis D seems to be associated with a worse prognosis in some cancers, but vitD supplementation failed to demonstrate a benefit in prostate cancer patients. The currently available evidence is insufficient to recommend vitD supplementation in cancer patients in clinical practice.
Vitamin D; Vitamin D receptor; Neoplasm; Prognosis
Related Articles
Seasonal variation of serum 25-hydroxyvitamin D levels in adult patients with inflammatory bowel disease
Bours, P. H. A.
Wielders, J. P. M.
Vermeijden, J. R.
van de Wiel, A.
Osteoporosis International
Patients with inflammatory bowel disease (IBD) are at risk of osteoporosis. Vitamin D (vitD) deficiency is known as a risk factor of osteoporosis. We observed low vitD blood levels in adult IBD patients both at the end of summer and winter. Furthermore, effects of oral vitD supplementation in (generally low) daily dosages were poor.
Patients with IBD are at risk of osteoporosis. This study evaluates seasonal vitD status, determinants of vitD deficiency and effects of vitD supplementation in adult IBD patients.
Patients were screened for vitD deficiency at the end of summer and winter using serum 25OHD3 (cut-off point, <50 nmol/L) combined with routine laboratory tests. A standardized questionnaire was used for demographic/lifestyle data i.e. IBD activity, health behaviour and vitD intake through diet and ultraviolet light.
Late-summer, 39% of the included 316 patients were vitD deficient. Late-winter, 57% of the follow-up patients (n = 281) were deficient. Independent protective determinants of vitD deficiency were oral vitD supplementation (summer/winter: odds ratio [OR], 0.52 [95% confidence interval [CI], 0.29–0.94]/OR, 0.44 [95% CI, 0.26–0.75]), recent sun holiday (summer: OR, 0.42 [95% CI, 0.24–0.74]) and regular solarium visits (summer/winter: OR, 0.28 [95% CI, 0.13–0.63]/OR, 0.17 [0.06–0.50]). IBD activity (p = 0.031), red blood cell distribution width (RDW; p = 0.04) and erythrocyte sedimentation rate (p = 0.03) were associated with low vitD levels using univariate analyses of the extreme 25OHD quartiles. In a subgroup with vitD supplementation, still 30% (late-summer) and 44% (late-winter) were vitD deficient.
VitD deficiency is common in IBD patients, but prevalence might be comparable with the general population. Ultraviolet light is essential for adequate vitD levels. Effects of oral vitD supplementation in (generally low) daily dosages are poor. Determinants for low vitD levels were IBD activity and elevated inflammatory markers, suggesting that increased risk of osteoporosis in IBD might be more related to the inflammation than to vitD deficiency.
Inflammatory bowel disease; Osteoporosis; Pathophysiology; Prevalence; Seasonal variation; Serum 25-hydroxyvitamin D
Related Articles
Decreased Serum Vitamin D Levels in Children with Asthma are Associated with Increased Corticosteroid Usage
Searing, Daniel A.
Zhang, Yong
Murphy, James R.
Hauk, Pia J.
Goleva, Elena
Leung, Donald Y. M.
The Journal of allergy and clinical immunology
There is little knowledge about clinical variables associated with vitamin D (vitD) insufficiency in asthmatic children.
To investigate disease variables associated with vitD insufficiency in childhood asthma and interaction of vitD with corticosteroid-mediated anti-inflammatory responses.
We analyzed 25-hydroxyvitamin D serum levels in 100 asthmatic children to investigate relationships between 25-hydroxyvitamin D levels and patient characteristics. We determined vitD effects on dexamethasone (DEX) induction of mitogen-activated protein kinase phosphatase-1 (MKP-1) and IL-10 in peripheral blood mononuclear cells (PBMC).
The median 25-hydroxyvitamin D serum level was 31 ng/mL. 47% of subjects had vitD levels in the insufficient range (<30 ng/mL), while 17% were vitD deficient (<20 ng/mL). Log10 IgE (p=0.01, ρ=−0.25) and the number of positive aeroallergen skin prick tests (p=0.02, ρ=−0.23) showed a significant inverse correlation with vitD, whereas FEV1% predicted (p =0.004, ρ=0.34) and FEV1/FVC ratio (p=0.01, ρ=0.30) showed a significant positive correlation with vitD. The use of inhaled steroids (p=0.0475), oral steroids (p=0.02), and total steroid dose (p=0.001), all showed significant inverse correlations with vitD. The amount of MKP-1 and IL-10 mRNA induced by vitD plus DEX was significantly greater than that induced by DEX alone (p<0.01). In an experimental model of steroid resistance where DEX alone did not inhibit T cell proliferation, addition of vitD to DEX resulted in significant dose dependent suppression of cell proliferation.
Corticosteroid use and worsening airflow limitation is associated with lower vitD serum levels in asthmatics. VitD enhances glucocorticoid action in asthmatic PBMC and enhances the immunosuppressive function of DEX in vitro.
Clinical Implications
Our study suggests that vitD supplementation may potentiate anti-inflammatory function of corticosteroids in asthmatics and thereby improve asthma control.
vitamin D; children; asthma
Related Articles
Vitamin D3 Decreases Parathyroid Hormone in HIV-Infected Youth Being Treated With Tenofovir: A Randomized, Placebo-Controlled Trial
Havens, Peter L.
Stephensen, Charles B.
Hazra, Rohan
Flynn, Patricia M.
Wilson, Craig M.
Rutledge, Brandy
Bethel, James
Pan, Cynthia G.
Woodhouse, Leslie R.
Van Loan, Marta D.
Liu, Nancy
Lujan-Zilbermann, Jorge
Baker, Alyne
Kapogiannis, Bill G.
Mulligan, Kathleen
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
In this randomized, double-blind, placebo-controlled trial of human immunodeficiency virus–infected youths aged 18–25, vitamin D3, 50000 IU once monthly for 3 months decreased parathyroid hormone in participants treated with tenofovir-containing antiretroviral regimens but not in those participants whose regimens did not contain tenofovir.
Background. The study goal was to determine the effect of vitamin D (VITD) supplementation on tubular reabsorption of phosphate (TRP), parathyroid hormone (PTH), bone alkaline phosphatase (BAP), and C-telopeptide (CTX) in youth infected with human immunodeficiency virus (HIV) receiving and not receiving combination antiretroviral therapy (cART) containing tenofovir disoproxil fumarate (TDF).
Methods. This randomized, double-blind, placebo-controlled multicenter trial enrolled HIV-infected youth 18–25 years based on stable treatment with cART containing TDF (n = 118) or no TDF (noTDF; n = 85), and randomized within those groups to vitamin D3, 50 000 IU (n = 102) or placebo (n = 101), administered at 0, 4, and 8 weeks. Outcomes included change in TRP, PTH, BAP, and CTX from baseline to week 12 by TDF/noTDF; and VITD/placebo.
Results. At baseline, VITD and placebo groups were similar except those on TDF had lower TRP and higher PTH and CTX. At week 12, 95% in the VITD group had sufficient serum 25-hydroxy vitamin D (25-OHD; ≥20 ng/mL), increased from 48% at baseline, without change in placebo (P < .001). PTH decreased in the TDF group receiving VITD (P = .031) but not in the noTDF group receiving VITD, or either placebo group. The decrease in PTH with VITD in those on TDF occurred with insufficient and sufficient baseline 25-OHD (mean PTH change, −7.9 and −6.2 pg/mL; P = .031 and .053, respectively).
Conclusions. In youth on TDF, vitamin D3 supplementation decreased PTH, regardless of baseline 25-OHD concentration.
Clinical Trials Registration. NCT00490412.
Related Articles
The Association of Concurrent Vitamin D and Sex Hormone Deficiency with Bone Loss and Fracture Risk in Older Men: The MrOS Study
Barrett-Connor, E
Laughlin, GA
Li, H
Nielson, CM
Wang, PY
Dam, TT
Cauley, JA
Ensrud, KE
Stefanick, ML
Lau, E
Hoffman, AR
Orwoll, ES
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Low 25-hydroxyvitamin D (VitD), low sex hormones (SH), and high sex hormone binding globulin (SHBG) levels are common in older men. We tested the hypothesis that combinations of low VitD, low SH, and high SHBG would have a synergistic effect on bone mineral density (BMD), bone loss, and fracture risk in older men. Participants were a random subsample of 1468 men (mean age 74) from the Osteoporotic Fractures in Men Study (MrOS) plus 278 MrOS men with incident non-spine fractures studied in a case-cohort design. "Abnormal" was defined as lowest quartile for VitD (<20 ng/ml), bioavailable testosterone (BioT, <163 ng/dl), and bioavailable estradiol (BioE, <11 pg/ml); and highest quartile for SHBG (>59 nM).
Overall, 10% had isolated VitD deficiency; 40% had only low SH or high SHBG; 15% had both SH/SHBG and VitD abnormality, and 35% had no abnormality. Compared to men with all normal levels, those with both SH/SHBG and VitD abnormality tended to be older, more obese, and to report less physical activity. Isolated VitD deficiency, and low BioT with or without low VitD, was not significantly related to skeletal measures. The combination of VitD deficiency with low BioE and/or high SHBG was associated with significantly lower baseline BMD and higher annualized rates of hip bone loss than SH abnormalities alone or no abnormality. Compared to men with all normal levels, the multivariate-adjusted hazard ratio (95% CI) for incident non-spine fracture during 4.6 yr median follow-up was 1.2 (0.8–1.8) for low VitD alone; 1.3 (0.9–1.9) for low BioE and/or high SHBG alone; and 1.6 (1.1–2.5) for low BioE/high SHBG plus low VitD.
In summary, adverse skeletal effects of low sex steroid levels were most pronounced in older men with low VitD levels. The presence of low VitD in the presence of low BioE/high SHBG may contribute substantially to poor skeletal health.
bone loss; fracture; older men; sex hormones; vitamin
Related Articles
Vitamin D Status and Related Factors in Newborns in Shanghai, China
Yu, Xiaodan
Wang, Weiye
Wei, Zhenzhen
Ouyang, Fengxiu
Huang, Lisu
Wang, Xia
Zhao, Yanjun
Zhang, Huijuan
Zhang, Jun
With the increasing recognition of the importance of the non-skeletal effects of vitamin D (VitD), more and more attention has been drawn to VitD status in early life. However, the VitD status of newborns and factors that influence VitD levels in Shanghai, China, remain unclear. A total of 1030 pregnant women were selected from two hospitals in Shanghai, one of the largest cities in China located at 31 degrees north latitude. Umbilical cord serum concentrations of 25-hydroxy vitamin D [25(OH)D] were measured by LC-MS-MS, and questionnaires were used to collect information. The median cord serum 25(OH)D concentration was 22.4 ng/mL; the concentration lower than 20 ng/mL accounted for 36.3% of the participants, and the concentration lower than 30 ng/mL for 84.1%. A multivariable logistic regression model showed that the determinants of low 25(OH)D status were being born during autumn or winter months and a lack of VitD-related multivitamin supplementation. The relative risk was 1.7 for both autumn (95% CI, 1.1–2.6) and winter (95% CI, 1.1–2.5) births (p < 0.05). VitD-related multivitamin supplementation more than once a day during pregnancy reduced the risk of VitD deficiency [adjusted OR (aOR) = 0.6, 95% CI (0.45–1.0) for VitD supplementation] (p < 0.05). VitD deficiency and insufficiency are common in newborns in Shanghai, China, and are independently associated with season and VitD supplementation. Our findings may assist future efforts to correct low levels of 25(OH)D in Shanghai mothers and their newborn children.
vitamin D; related factors; newborn
Related Articles
Vitamin D supplementation during exercise training does not alter inflammatory biomarkers in overweight and obese subjects
Carrillo, Andres E.
Flynn, Michael G.
Pinkston, Catherine
Markofski, Melissa M.
Jiang, Yan
Donkin, Shawn S.
Teegarden, Dorothy
European journal of applied physiology
The purpose of this study was to examine the effects of vitamin D supplementation on inflammatory biomarkers in overweight and obese adults participating in a progressive resistance exercise training program. Twenty-three (26.1±4.7 y) overweight and obese (BMI: 31.3±3.2 kg·m−2) adults were randomized into a double-blind vitamin D supplementation (VitD, 4000 IU/d, female=5; male=5) or placebo (PL, female=7; male=6) intervention trial. Both groups performed 12 wk (three d/wk) of progressive resistance exercise training (three sets of eight exercises) at 70 – 80% of one repetition maximum. Whole blood lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) α production as well as circulating C-reactive protein (CRP), TNFα, interleukin 6 (IL-6), and alanine aminotransferase (ALT) were assessed at baseline and after the 12 wk intervention. No main effects of group or time were detected for circulating CRP, TNFα, IL-6 and ALT. As expected, when PL and VitD groups were combined, there was a significant correlation between percent body fat and CRP at baseline (r=0.45, P=0.04), and between serum 25OHD and CRP at 12 weeks (r=0.49, P=0.03). The PL group had a significant increase in 25 μg/ml LPS+polymixin B-stimulated TNFα production (P=0.04), and both groups had a significant reduction in unstimulated TNFα production (P<0.05) after the 12 week intervention. Vitamin D supplementation in healthy, overweight and obese adults participating in a resistance training intervention did not augment exercise-induced changes in inflammatory biomarkers.
25-hydroxyvitamin D; resistance training; inflammation; tumor necrosis factor α; C-reactive protein; cytokine
Related Articles
Cardiovascular effects of cholecalciferol treatment in dialysis patients – a randomized controlled trial
Mose, Frank H
Vase, Henrik
Larsen, Thomas
Kancir, Anne SP
Kosierkiewic, Renata
Jonczy, Bartlomiej
Hansen, Annebirthe B
Oczachowska-Kulik, Anna E
Thomsen, Ingrid M
Bech, Jesper N
Pedersen, Erling B
BMC Nephrology
Patients on chronic dialysis are at increased risk of vitamin D deficiency. In observational studies plasma 25-hydroxyvitamin D (p-25(OH) D) levels are inversely correlated with plasma BNP and adverse cardiovascular outcomes. Whether a causal relation exists has yet to be established. The aim of this study was to test the hypothesis that cholecalciferol supplementation improves cardiac function and reduces blood pressure (BP) and pulse wave velocity (PWV) in patients on chronic dialysis.
In a randomized, placebo-controlled, double-blind study, we investigated the effect of 75 μg (3000 IU) cholecalciferol daily for 6 months, in patients on chronic dialysis. We performed two-dimensional echocardiography, with doppler and tissue-doppler imaging, 24-h ambulatory BP (24-h BP), PWV, augmentation index (AIx), central BP (cBP) and brain natriuretic peptide (BNP) measurements at baseline and after 6 months.
Sixty-four patients were allocated to the study. Fifty dialysis patients with a mean age of 68 years (range: 46–88) and baseline p-25(OH) D of 28 (20;53) nmol/l completed the trial. Cholecalciferol increased left ventricular (LV) volume, but had no impact on other parameters regarding LV structure or left atrial structure. LV systolic function, LV diastolic function, PWV, cBP, AIx and BNP were not changed in placebo or cholecalciferol group at follow-up. 24-h BP decreased significantly in placebo group and tended to decrease in cholecalciferol group without any difference between treatments.
Six months of cholecalciferol treatment in patients on chronic dialysis did not improve 24-h BP, arterial stiffness or cardiac function.
Trial registration
NCT01312714, Registration Date: March 9, 2011.
Cholecalciferol; Chronic kidney disease; Cardiac function; Brain natriuretic peptide; Blood pressure
Related Articles
Association of vitamin D and vitamin D receptor gene polymorphisms with chronic inflammation, insulin resistance and metabolic syndrome components in type 2 diabetic Egyptian patients
Mackawy, Amal M.H.
Badawi, Mohammed E.H.
Meta Gene
To date the published data concerning the possible interplay between vitamin D (VitD) and Vit D receptor (VDR) gene polymorphism with the immune/inflammatory mediators in type 2 diabetes mellitus (DM) is insufficient. Some of the immune non-classical actions of vitamin D may point to its role in the pathogenesis of type 2 DM through down-regulation of cytokines (IL-6). Although there is evidence to support a relationship among vitamin D status, chronic inflammation and insulin resistance, the underlying mechanism requires further exploration. We aimed to investigate the role of vitamin D in chronic inflammation and insulin resistance in type 2 DM. Moreover, to examine the association of VDR gene polymorphisms [VDR 2228570 C > T (FokI); VDR 1544410 A > G (BsmI)] with the components of metabolic syndrome (MetSyn) in type 2 diabetic Egyptian patients .
Subjects and methods
A total of 190 subjects were enrolled in this study, 60 controls and 130 type 2 diabetic patients (Group II). Group II was subdivided into 63 patients without MetSyn (subgroup IIa) and 67 patients with MetSyn (subgroup IIb). Genetic analysis for VDR gene polymorphisms was done in all subjects. VitD and IL-6 plasma levels were estimated.
The TT genotype for the VDR FokI was significantly more frequent in subgroup IIb than in subgroup IIa and controls (X2 = 6.83, P = 0.03 and X2 = 16.592, P = 0.000) respectively. The T allele was more frequent in the MetSyn group as compared to diabetics without MetSyn (p = 0.001), odds ratio (OR) and 95% CI for the T allele of C > T (FokI) = 2.30 (1.37–3.86). We did not detect any significant difference in VDR BsmI genotypes between patients and control groups (P = 0.947). FokI VDR was significantly associated with the lipid profile parameters, VitD and IL-6 plasma levels in subgroup IIa and associated with HOMA-IR, insulin, VitD, IL-6 levels, waist circumference (WC) and body mass index (BMI) in subgroup IIb while BsmI VDR variant was associated only with VitD values in both subgroups.
The present study suggests an interaction between VDR polymorphisms and important components of MetSyn, VitD and pro-inflammatory cytokines (IL-6). FokI VDR polymorphisms may be linked to mild inflammation and insulin resistance and might represent a genetic determinant for developing MetSyn in type 2 diabetic Egyptian patients. The challenge is determining the mechanisms of VitD action for recommendation of VitD supplementation that reduces the risks of MetSyn, insulin resistance and progression to type 2 diabetes.
VitD, Vitamin D; DM, diabetes mellitus; VDR, Vit D receptor; MetSyn, metabolic syndrome; HOMA, Homeostasis of Metabolic Assessment; WC, waist circumference; OR, odds ratio; BMI, body mass index; IL-6, interleukin -6; SOCS, suppressors of cytokine signaling; IRS, insulin receptor substrates; CRP, C-reactive protein; FBG, fasting blood glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; FPI, fasting plasma insulin; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; HPLC, High performance liquid chromatography; SD, standard deviation; X2, Chi-square; CI, confidence intervals; PGs, pro-inflammatory prostaglandins; NHANES III, National Health and Examination Survey; PTH, parathyroid hormone; Insulin resistance; Type 2 diabetes mellitus (DM); Metabolic syndrome; Vitamin D; Vitamin D Receptor gene; Polymorphisms; Pro-inflammatory cytokines; Interleukin-6 (IL-6)
Related Articles
Vitamin D status of early preterm infants and the effects of vitamin D intake during hospital stay
Monangi, Nagendra
Slaughter, Jonathan L
Dawodu, Adekunle
Smith, Carrie
Akinbi, Henry T
Archives of Disease in Childhood. Fetal and Neonatal Edition
To evaluate vitamin D (vitD) status in early preterm infants (EPTIs) at birth and during birth hospitalisation on current vitD intake.
Serum 25-hydroxyvitamin-D [25(OH)D] concentrations, vitD intake and risk factors for low vitD status were assessed in 120 infants born at ≤32 weeks gestation.
Mean (SD) serum 25(OH)D at birth was 46.2 (14.0) nmol/L with lower concentrations in infants born <28 weeks than at 28–32 weeks gestation, p=0.02. Serum 25(OH)D was <50 nmol/L in 63% of mothers, 64% of infants at birth and 35% of infants at discharge. Mean daily vitD intake was 289±96 IU at 4 weeks of age and 60% achieved 400 IU/day intake at discharge.
Serum 25(OH)D <50 nmol/L was widespread in parturient women and in EPTIs at birth and at discharge. Optimising maternal vitD status during pregnancy and improving postnatal vitD intake may enhance infant vitD status during hospitalisation.
Neonatology; Nutrition
Related Articles
Vitamin D2 Supplementation Amplifies Eccentric Exercise-Induced Muscle Damage in NASCAR Pit Crew Athletes
Nieman, David C.
Gillitt, Nicholas D.
Shanely, R. Andrew
Dew, Dustin
Meaney, Mary Pat
Luo, Beibei
This study determined if 6-weeks vitamin D2 supplementation (vitD2, 3800 IU/day) had an influence on muscle function, eccentric exercise-induced muscle damage (EIMD), and delayed onset of muscle soreness (DOMS) in National Association for Stock Car Auto Racing (NASCAR) NASCAR pit crew athletes. Subjects were randomized to vitD2 (n = 13) and placebo (n = 15), and ingested supplements (double-blind) for six weeks. Blood samples were collected and muscle function tests conducted pre- and post-study (leg-back and hand grip dynamometer strength tests, body weight bench press to exhaustion, vertical jump, 30-s Wingate test). Post-study, subjects engaged in 90 min eccentric-based exercise, with blood samples and DOMS ratings obtained immediately after and 1- and 2-days post-exercise. Six weeks vitD2 increased serum 25(OH)D2 456% and decreased 25(OH)D3 21% versus placebo (p < 0.001, p = 0.036, respectively), with no influence on muscle function test scores. The post-study eccentric exercise bout induced EIMD and DOMS, with higher muscle damage biomarkers measured in vitD2 compared to placebo (myoglobin 252%, 122% increase, respectively, p = 0.001; creatine phosphokinase 24 h post-exercise, 169%, 32%, p < 0.001), with no differences for DOMS. In summary, 6-weeks vitD2 (3800 IU/day) significantly increased 25(OH)D2 and decreased 25(OH)D3, had no effect on muscle function tests, and amplified muscle damage markers in NASCAR pit crew athletes following eccentric exercise.
delayed onset of muscle soreness (DOMS); myoglobin; creatine phosphokinase; muscle function testing; eccentric exercise; LC-MS/MS
Related Articles
Polymorphisms in GC and NADSYN1 Genes are associated with vitamin D status and metabolic profile in Non-diabetic adults
Foucan, Lydia
Vélayoudom-Céphise, Fritz-Line
Larifla, Laurent
Armand, Christophe
Deloumeaux, Jacqueline
Fagour, Cedric
Plumasseau, Jean
Portlis, Marie-Line
Liu, Longjian
Bonnet, Fabrice
Ducros, Jacques
BMC Endocrine Disorders
Our aim was to assess the associations between vitamin D (vitD) status, metabolic profile and polymorphisms in genes involved in the transport (Group-Component: GC) and the hydroxylation (NAD synthetase 1: NADSYN1) of 25 hydroxyvitamin D (25(OH)D) in non-diabetic individuals.
We conducted a cross-sectional study with 323 individuals recruited from the Health Center of Guadeloupe, France. The rs2282679 T > G and rs2298849 T > C in GC and rs12785878 G > T in NADSYN1 were genotyped.
Mean age was 46(range 18–86) years. 57% of participants had vitD insufficiency, 8% had vitD deficiency, 61% were overweight and 58% had dyslipidemia. A higher frequency of overweight was noted in women carrying rs2298849T allele v CC carriers (71% v 50%; P = 0.035). The rs2282679G allele was associated with increased risks of vitD deficiency and vitD insufficiency (OR =3.53, P = 0.008, OR = 2.34, P = 0.02 respectively). The rs2298849 TT genotype was associated with vitD deficiency and overweight (OR =3.4, P = 0.004 and OR = 1.76, P = 0.04 respectively) and the rs12785878 GG genotype with vitD insufficiency and dyslipidemia (OR = 1.80, P = 0.01 and OR = 1.72, P = 0.03 respectively). Based on the number of risk alleles for rs2282679 and rs12785878 combined, a genotype score of 3 (vs. 0–1) was associated with a 5.5 ng/mL average reduction in serum 25(OH)D levels (P = 0.001).
The GC and NADSYN1 genes are associated with the vitamin D status and might contribute to dyslipidemia and overweight independently of 25(OH)D levels.
Dyslipidemia; Overweight; Vitamin D; NAD synthetase 1; NADSYN; Group specific component; GC
Related Articles
Vitamin D deficiency reduces the benefits of progesterone treatment after brain injury in aged rats
Cekic, Milos
Cutler, Sarah M.
VanLandingham, Jacob W.
Stein, Donald G.
Neurobiology of aging
Administration of the neurosteroid progesterone (PROG) has been shown to be beneficial in a number of brain injury models and in two recent clinical trials. Given widespread vitamin D deficiency and increasing traumatic brain injuries (TBIs) in the elderly, we investigated the interaction of vitamin D deficiency and PROG with cortical contusion injury in aged rats. Vitamin D deficient (VitD-deficient) animals showed elevated inflammatory proteins (TNFα, IL-1β, IL-6, NFκB p65) in the brain even without injury. VitD-deficient rats with TBI, whether given PROG or vehicle, showed increased inflammation and greater open-field behavioral deficits compared to VitD-normal animals. Although PROG was beneficial in injured VitD-normal animals, in VitD-deficient subjects neurosteroid treatment conferred no improvement over vehicle. A supplemental dose of 1,25-dihydroxyvitamin D3 (VDH) given with the first PROG treatment dramatically improved results in VitD-deficient rats, but treatment with VDH alone did not. Our results suggest that VitD-deficiency can increase baseline brain inflammation, exacerbate the effects of TBI, and attenuate the benefits of PROG treatment; these effects may be reversed if the deficiency is corrected.
Aging; Inflammation; Progesterone; 1,25-Dihydroxyvitamin D3; Traumatic brain injury; Vitamin D deficiency
Related Articles
Vitamin D3 supplementation increases fibroblast growth factor-23 in HIV-infected youth treated with tenofovir disoproxil fumarate
Havens, Peter L
Hazra, Rohan
Stephensen, Charles B
Kiser, Jennifer J
Flynn, Patricia M
Wilson, Craig M
Rutledge, Brandy
Bethel, James
Pan, Cynthia G
Woodhouse, Leslie R
Van Loan, Marta D
Liu, Nancy
Lujan-Zilbermann, Jorge
Baker, Alyne
Kapogiannis, Bill G
Gordon, Catherine M
Mulligan, Kathleen
Antiviral therapy
Tenofovir (TDF) is associated with phosphaturia and elevated 1,25 dihydroxy vitamin D (1,25-OH(2)D). Fibroblast growth factor 23 (FGF23) causes phosphaturia and increases in response to elevated 1,25-OH(2)D. Vitamin D binding protein (VDBP) binds to 1,25-OH(2)D, decreasing its biologic activity, and is elevated in persons with higher plasma tenofovir concentrations. We compared FGF23 and VDBP before and after vitamin D3 (VITD) supplementation in youth treated with combination antiretroviral therapy (cART) containing or not containing TDF.
A randomized controlled trial in HIV+ youth ages 18–25 years enrolled participants based on cART treatment with TDF (TDF, N=118) or without TDF (no-TDF, N=85) and randomized within those groups to VITD (50,000 IU every four weeks) or placebo (PL). We measured FGF23 and VDBP and calculated free 1,25-OH(2)D at baseline and week 12, and compared changes by TDF treatment and VITD randomized group.
At baseline, serum FGF23 concentration showed a quadratic relationship with 1,25-OH(2)D most pronounced in the TDF group. At week 12, total and free 1,25-OH(2)D increased in the VITD but not PL groups, independent of TDF use. FGF23 increased in the TDF group receiving VITD, but there was no FGF23 change in the no-TDF group receiving VITD or the PL groups. The adjusted mean change in FGF23 from baseline to week 12 was +7.7 pg/mL in the TDF/VITD group, compared to −1.7 (no-TDF/VITD, p=0.010); −1.3 (TDF/PL, p=0.006); and +1.1 (no-TDF/PL, p=0.035).
These results suggest that TDF-containing cART may alter the FGF23 response to vitamin D supplementation in HIV-infected youth.
Related Articles
Effect of Folic Acid and Betaine Supplementation on Flow-Mediated Dilation: A Randomized, Controlled Study in Healthy Volunteers
Olthof, Margreet R
Bots, Michiel L
Katan, Martijn B
Verhoef, Petra
PLoS Clinical Trials
We investigated whether lowering of fasting homocysteine concentrations, either with folic acid or with betaine supplementation, differentially affects vascular function, a surrogate marker for risk of cardiovascular disease, in healthy volunteers. As yet, it remains uncertain whether a high concentration of homocysteine itself or whether a low folate status—its main determinant—is involved in the pathogenesis of cardiovascular disease. To shed light on this issue, we performed this study.
This was a randomized, placebo-controlled, double-blind, crossover study.
The study was performed at Wageningen University in Wageningen, the Netherlands.
Participants were 39 apparently healthy men and women, aged 50–70 y.
Participants ingested 0.8 mg/d of folic acid, 6 g/d of betaine, and placebo for 6 wk each, with 6-wk washout in between.
Outcome Measures:
At the end of each supplementation period, plasma homocysteine concentrations and flow-mediated dilation (FMD) of the brachial artery were measured in duplicate.
Folic acid supplementation lowered fasting homocysteine by 20% (−2.0 μmol/l, 95% confidence interval [CI]: −2.3; −1.6), and betaine supplementation lowered fasting plasma homocysteine by 12% (−1.2 μmol/l; −1.6; −0.8) relative to placebo. Mean (± SD) FMD after placebo supplementation was 2.8 (± 1.8) FMD%. Supplementation with betaine or folic acid did not affect FMD relative to placebo; differences relative to placebo were −0.4 FMD% (95%CI, −1.2; 0.4) and −0.1 FMD% (−0.9; 0.7), respectively.
Folic acid and betaine supplementation both did not improve vascular function in healthy volunteers, despite evident homocysteine lowering. This is in agreement with other studies in healthy participants, the majority of which also fail to find improved vascular function upon folic acid treatment. However, homocysteine or folate might of course affect cardiovascular disease risk through other mechanisms.
Editorial Commentary
Background: Evidence from observational studies indicates a link between high concentrations of homocysteine (an amino acid) in the blood and increased risk of cardiovascular disease. However, the basis for the link between homocysteine concentrations and cardiovascular disease risk is not clear. Supplementing the diet with B-vitamins lowers homocysteine levels, and large-scale trials are underway that will determine whether B-vitamin supplementation has an effect on cardiovascular outcomes, such as heart attacks and strokes. These trials also involve administration of folic acid as well as other B-vitamins. It is not obvious, however, whether the effects of B-vitamin supplementation arise as a result of homocysteine lowering or via some other biochemical pathway.
What this trial shows: Olthof and colleagues aimed to further understand the effects of homocysteine lowering by randomizing 40 healthy volunteer participants to receive either folic acid supplementation; placebo; or betaine, a nutrient that lowers homocysteine levels via a different biochemical pathway than folic acid. Each participant in the trial received each supplement for 6 wk, with a 6-wk washout period before the next supplement was given. The researchers then used a technique called flow-mediated dilation (FMD) to measure functioning of the main artery of the upper arm, as a surrogate for cardiovascular disease risk. In this trial, both folic acid and betaine supplementation significantly lowered homocysteine levels over the 6-wk supplementation period. However, both forms of supplementation failed to result in any significant change in functioning of the artery, as measured using FMD.
Strengths and limitations: In this trial 40 participants were recruited, and 39 were followed up to trial completion. A crossover design was used, with each participant receiving each supplement and a placebo in sequence. This method enabled a smaller number of participants to be used to answer the question of interest, as compared to parallel-group designs. The majority of participants in the trial were followed up. However, the trial's outcomes are surrogates for cardiovascular disease risk, measured over fairly short time periods, and no clinical outcomes were examined.
Contribution to the evidence: This trial adds to the evidence on the effects of nutrient supplementation on surrogate outcomes for cardiovascular disease risk. The results show that over a 6-wk study period, these surrogate outcomes are not affected by either folic acid or betaine supplementation.
Related Articles
A randomized control trial to assess the impact of vitamin D supplementation compared to placebo on vascular stiffness in chronic kidney disease patients
Levin, Adeera
Perry, Taylor
De Zoysa, Prathibha
Sigrist, Mhairi K
Humphries, Karin
Tang, Mila
Djurdjev, Ognjenka
BMC Cardiovascular Disorders
Vitamin D deficiency is associated with cardiovascular (CV) risk in multiple populations, including those with chronic kidney disease (CKD). The active form of the hormone (1,25 OH2D3) binds to receptors in multiple organs. CKD patients are deficient in both 25 Vitamin D and 1,25 OH2D3. Clinical trial data demonstrating the benefits of vitamin D formulations are limited, and fail to show significant benefits on CV outcomes, and have compared different compounds, in various populations, and focused on a variety of outcomes. A understanding of the mechanism by which different vitamin D compounds confer CV protection in CKD is important for the design of future studies.
This 3 arm randomized prospective double-blinded placebo-controlled study examining the impact of calcitriol (1,25 OH2D3) and 25-hydroxyvitamin D3 supplementation compared to placebo on vascular stiffness, as measured by pulse wave velocity (PWV). Patients are enrolled from 2 tertiary care institutions if they meet inclusion criteria (stable estimated glomerular filtration rate (eGFR) between 15-45ml/min, <±5ml/min change in previous 6 months), on stable doses of renin-angiotensin aldosterone system blockade. For those already receiving vitamin D therapies, a 3 month washout period before randomization is mandatory. Treatment duration is 6 months; medications are given thrice weekly in fixed doses. The primary outcome measure is Vascular stiffness, measured non-invasively by pulse wave velocity (PWV). Other measurements include BP, kidney function and serial blood levels of biomarkers. The primary analysis will compare any vitamin D therapy versus placebo for the primary outcome defined as the change of PWV from baseline to 6 months. Analysis of covariance will be used to detect differences between vitamin D preparations in the magnitude of reduction in PWV.
This study is novel in that we are using a robust study design in CKD patients (not on dialysis) comparing placebo to different forms of vitamin D supplementation in fixed doses, irrespective of baseline values. We hope to demonstrate the biological mechanistic effect of vitamin D supplementation on vascular function in order for this information to be used in designing larger randomized controlled trials.
Trial registration
Current Controlled Trials NCT01247311. Date of Registration: November 12, 2010.
Electronic supplementary material
The online version of this article (doi:10.1186/1471-2261-14-156) contains supplementary material, which is available to authorized users.
Chronic kidney disease; Vitamin D; Vascular stiffness; PWV; Randomized protocol study
Related Articles
Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study
Amrein, Karin
Sourij, Harald
Wagner, Gerit
Holl, Alexander
Pieber, Thomas R
Smolle, Karl Heinz
Stojakovic, Tatjana
Schnedl, Christian
Dobnig, Harald
Critical Care
Vitamin D deficiency is encountered frequently in critically ill patients and might be harmful. Current nutrition guidelines recommend very low vitamin D doses. The objective of this trial was to evaluate the safety and efficacy of a single oral high-dose vitamin D3 supplementation in an intensive care setting over a one-week observation period.
This was a randomized, double-blind, placebo-controlled pilot study in a medical ICU at a tertiary care university center in Graz, Austria. Twenty-five patients (mean age 62 ± 16yrs) with vitamin D deficiency [25-hydroxyvitamin D (25(OH)D) ≤20 ng/ml] and an expected stay in the ICU >48 hours were included and randomly received either 540,000 IU (corresponding to 13.5 mg) of cholecalciferol (VITD) dissolved in 45 ml herbal oil or matched placebo (PBO) orally or via feeding tube.
The mean serum 25(OH)D increase in the intervention group was 25 ng/ml (range 1-47 ng/ml). The highest 25(OH)D level reached was 64 ng/ml, while two patients showed a small (7 ng/ml) or no response (1 ng/ml). Hypercalcemia or hypercalciuria did not occur in any patient. From day 0 to day 7, total serum calcium levels increased by 0.10 (PBO) and 0.15 mmol/L (VITD; P < 0.05 for both), while ionized calcium levels increased by 0.11 (PBO) and 0.05 mmol/L (VITD; P < 0.05 for both). Parathyroid hormone levels decreased by 19 and 28 pg/ml (PBO and VITD, ns) over the seven days, while 1,25(OH)D showed a transient significant increase in the VITD group only.
This pilot study shows that a single oral ultra-high dose of cholecalciferol corrects vitamin D deficiency within 2 days in most patients without causing adverse effects like hypercalcemia or hypercalciuria. Further research is needed to confirm our results and establish whether vitamin D supplementation can affect the clinical outcome of vitamin D deficient critically ill patients.
EudraCT Number
German Clinical Trials Register (DRKS)
Related Articles
Vitamin K Supplementation in Postmenopausal Women with Osteopenia (ECKO Trial): A Randomized Controlled Trial
Cheung, Angela M
Tile, Lianne
Lee, Yuna
Tomlinson, George
Hawker, Gillian
Scher, Judy
Hu, Hanxian
Vieth, Reinhold
Thompson, Lilian
Jamal, Sophie
Josse, Robert
PLoS Medicine
Vitamin K has been widely promoted as a supplement for decreasing bone loss in postmenopausal women, but the long-term benefits and potential harms are unknown. This study was conducted to determine whether daily high-dose vitamin K1 supplementation safely reduces bone loss, bone turnover, and fractures.
Methods and Findings
This single-center study was designed as a 2-y randomized, placebo-controlled, double-blind trial, extended for earlier participants for up to an additional 2 y because of interest in long-term safety and fractures. A total of 440 postmenopausal women with osteopenia were randomized to either 5 mg of vitamin K1 or placebo daily. Primary outcomes were changes in BMD at the lumbar spine and total hip at 2 y. Secondary outcomes included changes in BMD at other sites and other time points, bone turnover markers, height, fractures, adverse effects, and health-related quality of life. This study has a power of 90% to detect 3% differences in BMD between the two groups. The women in this study were vitamin D replete, with a mean serum 25-hydroxyvitamin D level of 77 nmol/l at baseline. Over 2 y, BMD decreased by −1.28% and −1.22% (p = 0.84) (difference of −0.06%; 95% confidence interval [CI] −0.67% to 0.54%) at the lumbar spine and −0.69% and −0.88% (p = 0.51) (difference of 0.19%; 95% CI −0.37% to 0.75%) at the total hip in the vitamin K and placebo groups, respectively. There were no significant differences in changes in BMD at any site between the two groups over the 2- to 4-y period. Daily vitamin K1 supplementation increased serum vitamin K1 levels by 10-fold, and decreased the percentage of undercarboxylated osteocalcin and total osteocalcin levels (bone formation marker). However, C-telopeptide levels (bone resorption marker) were not significantly different between the two groups. Fewer women in the vitamin K group had clinical fractures (nine versus 20, p = 0.04) and fewer had cancers (three versus 12, p = 0.02). Vitamin K supplements were well-tolerated over the 4-y period. There were no significant differences in adverse effects or health-related quality of life between the two groups. The study was not powered to examine fractures or cancers, and their numbers were small.
Daily 5 mg of vitamin K1 supplementation for 2 to 4 y does not protect against age-related decline in BMD, but may protect against fractures and cancers in postmenopausal women with osteopenia. More studies are needed to further examine the effect of vitamin K on fractures and cancers.
Trial registration: ClinicalTrials.gov (#NCT00150969) and Current Controlled Trials (#ISRCTN61708241)
Angela Cheung and colleagues investigate whether vitamin K1 can prevent bone loss among postmenopausal women with osteopenia.
Editors' Summary
Osteoporosis is a bone disease in which the bones gradually become less dense and more likely to break. In the US, 10 million people have osteoporosis and 18 million have osteopenia, a milder condition that precedes osteoporosis. In both conditions, insufficient new bone is made and/or too much old bone is absorbed. Although bone appears solid and unchanging, very little bone in the human body is more than 10 y old. Old bone is continually absorbed and new bone built using calcium, phosphorous, and proteins. Because the sex hormones control calcium and phosphorous deposition in the bones and thus bone strength, the leading cause of osteoporosis in women is reduced estrogen levels after menopause. In men, an age-related decline in testosterone levels can cause osteoporosis. Most people discover they have osteoporosis only when they break a bone, but the condition can be diagnosed and monitored using bone mineral density (BMD) scans. Treatments can slow down or reverse bone loss (antiresorptive therapies) and some (bone formation therapies) can even make bone and build bone tissue.
Why Was This Study Done?
Although regular exercise and a healthy diet can help to keep bones strong, other ways of preventing osteoporosis are badly needed. Recently, the lay media has promoted vitamin K supplements as a way to reduce bone loss in postmenopausal women. Vitamin K (which is found mainly in leafy green vegetables) is required for a chemical modification of proteins called carboxylation. This modification is essential for the activity of three bone-building proteins. In addition, there is some evidence that low bone density and fractures are associated with a low vitamin K intake. However, little is known about the long-term benefits or harms of vitamin K supplements. In this study, the researchers investigate whether a high-dose daily vitamin K supplement can safely reduce bone loss, bone turnover, and fractures in postmenopausal women with osteopenia in a randomized controlled trial called the "Evaluation of the Clinical Use of Vitamin K Supplementation in Post-Menopausal Women With Osteopenia" (ECKO) trial.
What Did the Researchers Do and Find?
In the study, 440 postmenopausal women with osteopenia were randomized to receive 5mg of vitamin K1 (the type of vitamin K in North American food; the recommended daily adult intake of vitamin K1 is about 0.1 mg) or an inactive tablet (placebo) daily for 2 y; 261 of the women continued their treatment for 2 y to gather information about the long-term effects of vitamin K1 supplementation. All the women had regular bone density scans of their lower back and hips and were examined for fractures and for changes in bone turnover. After 2 y and after 4 y, lower back and hip bone density measurements had decreased by similar amounts in both treatment groups. The women who took vitamin K1 had 10-fold higher amounts of vitamin K1 in their blood than the women who took placebo and lower amounts of a bone formation marker; the levels of a bone resorption marker were similar in both groups. Over the 4-y period, fewer women in the vitamin K group had fractures (nine versus 20 women in the placebo group), and fewer had cancer (three versus 12). Finally, vitamin K supplementation was well tolerated over the 4-y period and adverse health effects were similar in the two treatment groups.
What Do These Findings Mean?
These findings indicate that a high daily dose of vitamin K1 provides no protection against the age-related decline in bone density in postmenopausal women with osteopenia, but that vitamin K1 supplementation may protect against fractures and cancers in these women. The apparent contradiction between the effects of vitamin K1 on bone density and on fractures could mean that vitamin K1 supplements strengthen bone by changing factors other than bone density, e.g., by changing its fine structure rather than making it denser. However, because so few study participants had fractures, the difference in the fracture rate between the two treatment groups might have occurred by chance. Larger studies are therefore needed to examine the effect of vitamin K1 on fractures (and on cancer) and, until these are done, high-dose vitamin K1 supplementation should not be recommended for the prevention of osteoporosis.
Additional Information.
Please access these Web sites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.0050196.
The US National Institute of Arthritis and Musculoskeletal and Skin Diseases provides detailed information about osteoporosis (in English and Spanish) and links to other resources, including an interactive web tool called Check Up On Your Bones
MedlinePlus provides links to additional information about osteoporosis (in English and Spanish)
The MedlinePlus Encyclopedia has a page about vitamin K
The UK Food Standards Agency provides information about vitamin K
Full details about the ECKO trial are available on the ClinicalTrials.gov Web site
The Canadian Task Force for Preventive Health Care provides recommendations on the prevention of osteoporosis and osteoporotic fractures in postmenopausal women
Osteoporosis Canada provides information on current topics related to osteoporosis
Related Articles
Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat
Refaat, Bassem
Ashour, Tariq Helal
El-Shemi, Adel Galal
International Journal of Clinical and Experimental Medicine
Objectives: To measure the effect of vitamin D3 (VitD) supplementation on erythrocyte indices, serum and kidney erythropoietin (EPO) in normal rats treated with Pegylated interferon-α (Peg-INF-α) and ribavirin (RBV). Materials and methods: Eighty male Wistar rats were divided equally into 8 groups. 'Control'; 'P': only received Peg-INF-α; 'PD': Peg-INF-α/VitD; 'PR': Peg-INF-α/RBV; 'PRD': Peg-INF-α/RBV/VitD; 'R': only received RBV; 'RD': RBV/VitD and 'VitD': only received vitamin D3. Peg-INF-α-2a was injected subcutaneously (6 µg/rat/week) for 4 weeks. RBV (4 mg/rat/day) and VitD (500 IU/rat/day) were given orally for 5 weeks. Blood samples were collected to measure erythrocyte indices and serum 25(OH) vitamin D. EPO was measured in serum samples and kidney specimens by ELISA. Results: Peg-INF-α alone did not affect the RBCs count, haemoglobin, serum and kidney EPO compared to control (P > 0.05). RBV significantly decreased (P < 0.05) the erythrocyte count, haemoglobin and EPO levels in kidney and serum, either individually (R group) or combined with Peg-INF-α (PR group), compared to 'Control' and 'P' groups. VitD prevented the development of anaemia and significantly increased the concentrations of EPO at serum and kidney levels in the 'RD' and 'PRD' groups compared to 'R' and 'PR' groups. There was a significant positive correlation between blood levels of VitD with serum and kidney EPO, Red cell count and haemoglobin concentrations. Conclusion: VitD could have a potential beneficial role in the prevention of ribavirin-induced anaemia by promoting endogenous EPO. Further studies are needed to explore the role of vitamin D in the prevention of ribavirin associated anaemia.
Anaemia; erythropoietin hormone; pegylated interferon-α; ribavirin and vitamin D
Related Articles
Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657)
Clark, Amy S
Chen, Jinbo
Kapoor, Shiv
Friedman, Claire
Mies, Carolyn
Esserman, Laura
DeMichele, Angela
Cancer Medicine
Laboratory studies suggest that vitamin D (vitD) enhances chemotherapy-induced cell death. The objective of this study was to determine whether pretreatment vitD levels were associated with response to neoadjuvant chemotherapy (NACT) in women with breast cancer. Study patients (n = 82) were enrolled on the I-SPY TRIAL, had HER2-negative tumors, and available pretreatment serum. VitD levels were measured via DiaSorin radioimmunoassay. The primary outcome was pathologic residual cancer burden (RCB; dichotomized 0/1 vs. 2/3). Secondary outcomes included biomarkers of proliferation, differentiation, and apoptosis (Ki67, grade, Bcl2, respectively) and 3-year relapse-free survival (RFS). Mean and median vitD values were 22.7 ng/mL (SD 11.9) and 23.1 ng/mL, respectively; 72% of patients had levels deemed "insufficient" (<30 ng/mL) by the Institute of Medicine (IOM). VitD level was not associated with attaining RCB 0/1 after NACT (univariate odds ratio [OR], 1.01; 95% CI, 0.96–1.05) even after adjustment for hormone receptor status (HR), grade, Ki67, or body mass index (BMI). Lower vitD levels were associated with higher tumor Ki67 adjusting for race (OR, 0.95; 95% CI, 0.90–0.99). VitD level was not associated with 3-year RFS, either alone (hazard ratio [HzR], 0.98; 95% CI, 0.95–1.02) or after adjustment for HR, grade, Ki-67, BMI, or response. VitD insufficiency was common at the time of breast cancer diagnosis among women who were candidates for NACT and was associated with a more proliferative phenotype. However, vitD levels had no impact on tumor response to NACT or short-term prognosis.
Breast cancer; neoadjuvant chemotherapy; response; vitamin D
Related Articles
Impact of Vitamin D Supplementation on Arterial Vasomotion, Stiffness and Endothelial Biomarkers in Chronic Kidney Disease Patients
Chitalia, Nihil
Ismail, Tuan
Tooth, Laura
Boa, Frances
Hampson, Geeta
Goldsmith, David
Kaski, Juan Carlos
Banerjee, Debasish
PLoS ONE
Cardiovascular events are frequent and vascular endothelial function is abnormal in patients with chronic kidney disease (CKD). We demonstrated endothelial dysfunction with vitamin D deficiency in CKD patients; however the impact of cholecalciferol supplementation on vascular stiffness and vasomotor function, endothelial and bone biomarkers in CKD patients with low 25-hydroxy vitamin D [25(OH)D] is unknown, which this study investigated.
We assessed non-diabetic patients with CKD stage 3/4, age 17–80 years and serum 25(OH)D <75 nmol/L. Brachial artery Flow Mediated Dilation (FMD), Pulse Wave Velocity (PWV), Augmentation Index (AI) and circulating blood biomarkers were evaluated at baseline and at 16 weeks. Oral 300,000 units cholecalciferol was administered at baseline and 8-weeks.
Clinical characteristics of 26 patients were: age 50±14 (mean±1SD) years, eGFR 41±11 ml/min/1.73 m2, males 73%, dyslipidaemia 36%, smokers 23% and hypertensives 87%.
At 16-week serum 25(OH)D and calcium increased (43±16 to 84±29 nmol/L, p<0.001 and 2.37±0.09 to 2.42±0.09 mmol/L; p = 0.004, respectively) and parathyroid hormone decreased (10.8±8.6 to 7.4±4.4; p = 0.001). FMD improved from 3.1±3.3% to 6.1±3.7%, p = 0.001.
Endothelial biomarker concentrations decreased: E-Selectin from 5666±2123 to 5256±2058 pg/mL; p = 0.032, ICAM-1, 3.45±0.01 to 3.10±1.04 ng/mL; p = 0.038 and VCAM-1, 54±33 to 42±33 ng/mL; p = 0.006. eGFR, BP, PWV, AI, hsCRP, von Willebrand factor and Fibroblast Growth Factor-23, remained unchanged.
This study demonstrates for the first time improvement of endothelial vasomotor and secretory functions with vitamin D in CKD patients without significant adverse effects on arterial stiffness, serum calcium or FGF-23.
Trial Registration
ClinicalTrials.gov NCT02005718
Related Articles
Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial
Longenecker, Chris T
Hileman, Corrilynn O
Carman, Teresa L
Ross, Allison C
Seydafkan, Shabnam
Brown, Todd T
Labbato, Danielle E
Storer, Norma
Tangpricha, Vin
McComsey, Grace A
Antiviral therapy
Studies suggest that vitamin D deficiency is a risk factor for cardiovascular disease and diabetes. Vitamin D deficiency is prevalent in HIV patients but the effect of vitamin D supplementation on cardiovascular risk in this population is unknown.
We conducted a randomized, double-blind, placebo-controlled trial among 45 HIV-infected adults in Cleveland (OH, USA) on stable antiretroviral therapy with durable virological suppression and a baseline serum 25-hydroxyvitamin D level of ≤20 ng/ml. Participants were randomized 2:1 to vitamin D3 4,000 IU daily or placebo for 12 weeks. The primary outcome was a change in flow-mediated brachial artery dilation (FMD).
Baseline demographics were similar except for age (vitamin D versus placebo, mean ±SD 47 ±8 versus 40 ±10 years; P=0.009). Both groups had reduced FMD at baseline (median values 2.9% [IQR 1.6–4.8] for vitamin D versus 2.5% [IQR 1.7–6.4] for placebo; P=0.819). Despite an increase in the concentration of serum 25-hydroxyvitamin D from baseline to 12 weeks (5.0 ng/ml [IQR −0.9–7.4] versus −1.9 ng/ml [IQR −4.0–0.1] for vitamin D versus placebo, respectively; P=0.003), there was no difference in FMD change (0.55% [IQR −1.05–2.13] versus 0.29% [IQR −1.61–1.77]; P=0.748). Vitamin D supplementation was associated with a decrease in total and non-high-density lipoprotein cholesterol, and an increase in indices of insulin resistance.
Among HIV-infected individuals with vitamin D deficiency, supplementation with 4,000 IU vitamin D3 daily for 12 weeks modestly improved vitamin D status and cholesterol but worsened insulin resistance without change in endothelial function. The mechanisms of resistance to standard doses of vitamin D and the complex role of vitamin D in glucose metabolism in this population require further investigation.
Related Articles
The Peroxisome Proliferator Activated Receptor‐γ Pioglitazone Improves Vascular Function and Decreases Disease Activity in Patients With Rheumatoid Arthritis
Marder, Wendy
Khalatbari, Shokoufeh
Myles, James D.
Hench, Rita
Lustig, Susan
Yalavarthi, Srilakshmi
Parameswaran, Aishwarya
Brook, Robert D.
Kaplan, Mariana J.
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Rheumatoid arthritis (RA) is associated with heightened mortality due to atherosclerotic cardiovascular disease (CVD). Inflammatory pathways in RA negatively affect vascular physiology and promote metabolic disturbances that contribute to CVD. We hypothesized that the peroxisome proliferator activated receptor‐γ (PPAR‐γ) pioglitazone could promote potent vasculoprotective and anti‐inflammatory effects in RA.
Methods and Results
One hundred forty‐three non‐diabetic adult RA patients (76.2% female, age 55.2±12.1 [mean±SD]) on stable RA standard of care treatment were enrolled in a randomized, double‐blind placebo controlled crossover trial of 45 mg daily pioglitazone versus placebo, with a 3‐month duration/arm and a 2‐month washout period. Pulse wave velocity of the aorta (PWV), brachial artery flow mediated dilatation (FMD), nitroglycerin mediated dilatation (NMD), microvascular endothelial function (reactive hyperemia index [RHI]), and circulating biomarkers of inflammation, insulin resistance, and atherosclerosis risk all were quantified. RA disease activity was assessed with the 28‐Joint Count Disease Activity Score (DAS‐28) C‐reactive protein (CRP) and the Short Form (36) Health Survey quality of life questionnaire. When added to standard of care RA treatment, pioglitazone significantly decreased pulse wave velocity (ie, aortic stiffness) (P=0.01), while FMD and RHI remained unchanged when compared to treatment with placebo. Further, pioglitazone significantly reduced RA disease activity (P=0.02) and CRP levels (P=0.001), while improving lipid profiles. The drug was well tolerated.
Addition of pioglitazone to RA standard of care significantly improves aortic elasticity and decreases inflammation and disease activity with minimal safety issues. The clinical implications of these findings remain to be established.
Clinical Trial Registration
URL: ClinicalTrials.gov Unique Identifier: NCT00554853.
drugs; inflammation; rheumatoid arthritis; vasodilation
Related Articles
Results 1-25 (579251)
« Previous
Go to page number:
Next »
Remove citation from clipboard
Add citation to clipboard
This will clear all selections from your clipboard. Do you wish proceed?
Clipboard is full! Please remove an item and try again.
Contact Us
PubMed Central Canada is a service of the
Canadian Institutes of Health Research
(CIHR) working in partnership with the National Research Council's
national science library
in cooperation with the
National Center for Biotechnology Information
at the
U.S. National Library of Medicine
(NCBI/NLM). It includes content provided to the
PubMed Central International archive
by participating publishers.


text:
Ford, GM Sign On As White House Unveils 54.5mpg Standard
General Motors and Ford have signed off on a deal to increase fuel efficiency to 54.5 miles per gallon by 2025.
The Detroit News reports that the two auto giants are the first to sign memorandums of understanding on the 2017-2015 fuel efficiency standards, and that other carmakers are preparing to sign MOUs by the end of the day.
The federal government is preparing MOUs that reflect a last-minute change to the agreement, the newspaper said, after talks with automakers and the state of California went on until 1 a.m. this morning.
Hyundai U.S. chief John Krafcik told the paper the deal would "right-size the fleet. There are going to be fewer vehicles over there bought for the occasional need to carry nine people or seven people."
Reader Comments
One way to increase fuel efficiency greatly is to utilize waste heat from the muffler system,
known as GreenPower Muffler system.
I see an opportunity for biomass fuels derived from the gd salamanders that are ruining the town of Branford.
This sounds like good news. We really need these big companies who have such a great impact on the industry to step up to the plate and show their commitment to help out the environment. This usually has a positive ripple effect through the industry and encourages more people and other companies to do their part as well.
Fuel standards are a poor way to reduce GHGs, reduce dependence on foreign oil, and the like. When it becomes cheaper for people to drive (via greater MPG) they drive more. Obama seems to just be pandering to the greens, with inefficient economic policies. Every economist knows that market-based incentives (i.e taxes and subsidies) are the BEST way government can intervene in the private sector. One might argue that 'taxes' are dead on arrival, but they are only dead on arrival because Obama hasn't fought for them. The republican presidential field is weak, his competition is weak, lets see the 'change' we voted for instead of the usual, minimal, environmentalism that the Obama administration is building a reputation for.
Energy Manager News
- Two Studies Show the State of Energy Efficiency
- Phoenix Airport LED Project Moves Along
- Maine Businesses Shut Out of Power Program
- Stay Cool This Summer While Avoiding These Common Summer Pitfalls
- Coalition Seeks to Stop SCE&G's Blank Check
- NARUC Releases DER Draft Rate Design Manual
- Behind the Meter Podcast: Pushing Sustainability, Efficiency with Green Leases
- The Tricky World of Portable Commercial Air Conditioners

subset: commoncrawl


text:
well that's just, like, your opinion, man
Recent Comments
|32 weeks 4 days ago
|Just so all are clear, that
Just so all are clear, that is not the Adrian Arrington from Michigan but instead from Eastern Illinois who filed an action against the NCAA a few years ago. I had the same question when the litigation was filed and looked it up then!
Sent from MGoBlog HD for iPhone & iPad
|1 year 28 weeks ago
|Most importantly...
Did anyone call this???
|2 years 10 weeks ago
|Eng 325 - Rubadeau
John is a fantastic professor and seemed to find a way to challenge all of his students to dedicate themselves to improving their writing.
Eng 401 analyzing the Bible's literary aspects with Williams 2nd. Ian Fulcher also taught an English class about comic books but I can't remember the number. Among the comics we analyzed were what I believe will be the comic inspiring the Batman-Superman movie as well as Maus.
|2 years 20 weeks ago
Everything changed after that shot!
Burke and Novak T2.
|2 years 23 weeks ago
the games!
|2 years 34 weeks ago
|I have never turned on Devin
True blue and the best option we have right now. He has never turned on his teammates or coaches. Just tries to do his best and keeps on fighting. So classy in post game pressers despite the clear pain he is in.
|2 years 47 weeks ago
|No one seeing the positive here?
Clearly, the players are so focused during the games that they have no idea what's going on in the crowd. No? Okay, I tried.
|2 years 47 weeks ago
|Next week?
Looks like you're set for this week. If you are back next week, your headquarters should be somewhere closer to campus (Near Hoover and State St? closer to Hoover near Elbel?) so that students or other fans coming from campus before the game will pass you on way to the stadium. Good luck!
|3 years 14 weeks ago
This means D-Rose should be back this week!!
|3 years 15 weeks ago
|Very cool
Thanks for sharing. Hope Denard gets a great offensive mind to put him in a position to succeed. Also very intrigued by your sig line. What's that from?
|3 years 25 weeks ago
|Pretty funny
the ND image is no one. I see what you did there EA Sports.
|3 years 28 weeks ago
Thought this was going to include the vids.
|3 years 33 weeks ago
Rookie mistake. I wanted to say your post was extremely funny, not moderately funny. OOPS. No idea what I just did.
|3 years 34 weeks ago
|Not in my opinion
He seemed to be running the same PA passes and roll outs in the second half and seemed his usual nimble self while trying to evade the rush. Hope it's more of a precaution since there's so much time before the next game.
|3 years 34 weeks ago
|Look forward to reading it
I want to know if he heard someone call timeout from the bench. Also, will be interesting to hear other stories from the Fab Five days to add to the 30 on 30 special. And, of course, the whole Ed Martin story would be nice too.
|3 years 34 weeks ago
|Can someone please
make a GIF of the FSU fan going "what happened...what happened...scream" after that last fumble? 10:21 left 3q. Hilarious. Also, crazy tale of two halves in this UF-FSU game.
|3 years 35 weeks ago
|The Anti-Zoolander
He CAN turn left. Game changer.
|3 years 35 weeks ago
|Look forward to it
Thanks for the heads up. Will be very interesting to see what stats they discuss. I believe I read an article last year that applications to Alabama both increased tremendously post national championship years. Will be interesting to see what the theme is considering the Towson trailer but also that UM was interviewed.
|3 years 35 weeks ago
|Sounds like a Devin Gardner stat line
Is Devin the man to be the first Michigan QB since Henson to lead us to a win at Ohio? Bootleg td perhaps?
|3 years 35 weeks ago
This reminds me of me after seeing UCLA upset USC in 2006. I was sure that was all Michigan needed to play Ohio in a rematch. Then, Danielson-Meyer politicking (you can't play for a tltle without winning a conference!) and Florida happened...
|3 years 35 weeks ago
|Great job, Al
Good luck to the Bucks to prepare for all that plus the other O seen during Weeks 1-11.
|3 years 37 weeks ago
Will have to wait another week to get BIG tickets. Sigh.
|3 years 37 weeks ago
|Great job, Devin!
Short week to turn in the WR card and start reading coverages and thinking like a qb. Maybe split snaps the rest of the year to protect Denard's arm and have defenses prep for multiple qbs? Also would help get him more game speed reps for 2013.
Finally, didn't notice much drop off from WR production by moving him back to qb. But, should say was just Minny.
|3 years 38 weeks ago
|I believe...
Denard will be the second Michigan player to receive a standing ovation at the Horseshoe. It is his destiny.
Forgot the main part of this original post. Defensively, yes. Offensively, no. Fortunately, the two units that are strongest/weakest for both teams match up.
|3 years 38 weeks ago
|Very impressed by the defense
Have done the job in 7/8 games to give the offense a shot. And well , the Alabama game, they are given a pass.
|3 years 38 weeks ago
Gotta be that funny bone thing right? Hoke says it happens time to time and he loses sense in the arm. Hopefully, he has regained the feeling.
|3 years 38 weeks ago
Think this Denard and Fitz combo will wear Neb down. Watch for breakdowns in d in 2nd half.
|3 years 38 weeks ago
|That makes sense
|3 years 38 weeks ago
Now that we've missed on points, I feel I should reflect on the replay standard. Conclusive evidence to overturn right? I didn't see that from the angles shown.
|3 years 38 weeks ago
earning that jersey #!!
|3 years 38 weeks ago
|fitz sighting!
|3 years 38 weeks ago
no kick catch interference? expect a flag thrown while game was at commercial.
|3 years 39 weeks ago
|Get well, soon Braxton
Want to see a classic game in the 'shoe on November 24. Side note: Denard will be the 2nd player to get a standing O at Ohio Stadium. It is his destiny.
|3 years 39 weeks ago
|Great video
60 minutes. Now, beat Nebraska!
|3 years 39 weeks ago
You'll get hated on by most for this but I think Rich is a great coach and found a great fit. And here's to Hoke. Someone who truly does "get" Michigan.
The Hoke-Rodriguez Rose Bowl in 2014 will be a fun one.
|3 years 39 weeks ago
|No prob
I remember the game more for the Shazor hit shortly thereafter but I know Rivas gave them the lead late.
|3 years 39 weeks ago
Undefeated at home under Hoke. Lezgo!
|3 years 39 weeks ago
|Garrett Rivas @ Purdue 2004
16-14 final I believe.
|3 years 41 weeks ago
|Credit where credit is due
That was great.
|3 years 41 weeks ago
|My fave
So good!
|3 years 41 weeks ago
|Clap Clap Clap
Well played, sir. I hope for a similar score in Lincoln this year. It does appear that Nebraska has no problems giving up points.
|3 years 41 weeks ago
|Classic video
My favorite part: "What's your name?" LOL
|3 years 42 weeks ago
|Let's get it!
Side question: Who is the high school teammate playing for WMU or Toledo?
|3 years 42 weeks ago
WHY IS AVANT DOING THIS???? Who provided him with the jersey, pads, and cleats to make that catch against Northwestern???
Haha. I thought the original poster was actually asking a serious question. This was a fun post.
|3 years 42 weeks ago
|I seem to remember...
a crazy scramble and deep completion from Henson in this game but didn't see it in the video.
|3 years 42 weeks ago
|Tough result
Great golf. Medinah was spectacular as well. A major needs to go back there ASAP.
|3 years 42 weeks ago
|Monty & Sergio
Something about this event brings out the best in those guys. Poulter to some extent too.
It's weird there is no official color for the Euros. Saw bright orange and now purpleish.
|3 years 42 weeks ago
|Great start
Love how Keegan is firing up the crowd.
|3 years 43 weeks ago
I think he'll receive the loudest cheer for a senior that I've ever heard at Senior Day. I never thought anyone would get more than Mike Hart did a few years ago.
|3 years 43 weeks ago
|So Denard is...
Brett Favre-ish! Great and bad! Not a bad comparison, I suppose for a qb.
|3 years 43 weeks ago
|If you think about it...
he has 12-14 opportunities to showcase what he has been doing 351-353 days. It sucks one of his bad days came during one of those 12-14. Happens to all of us! Big Ten season awaits. He'll be ready. His apology video made me think back to the Tebow-Ole Miss promise and that ended well for UF.
|3 years 44 weeks ago
|I guess I should put down my guesses
Denard will need to scramble for a lot due to that D-Line's improvement. But, his scrambling will also lead to defenders forgetting their assignments and coming up to stop him which allows receivers to break free...so...
17/31, 241, 2td, 2int
22 carries, 187 yards, 1 td
|3 years 44 weeks ago
Denard has been close so many times. I actually thought he might get it during the Rich Rod era because so many teams needed to cheat against the run. Alas, record still stands at 4!
|3 years 44 weeks ago
|Rough year for the BIG
Crazy # of injuries it seems compared to last few years.
|3 years 44 weeks ago
|Five td passes would be nice....
as it would be a school record. Shocking to me that of all the great pocket passers we've had, no one has thrown for more than 4 in one game. For Denard to do it would be prettttty sweeeet.
|3 years 45 weeks ago
|Perhaps he didn't want to be associated with UCONN
when MEEEEECHIGAN comes to Connecticut and leaves with a 70-7 victory.
I'm mixed, and on the same lines with other folks. Great wins, some sketchiness. Solid career.
|3 years 45 weeks ago
|I will be there
But more importantly...will RoosterMan (of US Open, Open Championship, and Notre Dame-Navy fame) be there??
|3 years 45 weeks ago
Would like to see our secondary get tested again before ND. Will Air Force or Mass have any sort of passing attack to test our corners and non-Kovacs safeties?
|3 years 45 weeks ago
|Great vid
Will look for him on an NFL field next year.
|3 years 47 weeks ago
Probably 30-25 for USC, 20-25 for Michigan, some for OU and some for FSU.
|3 years 47 weeks ago
To Roundtree for td.
|3 years 47 weeks ago
|Good year to schedule Boise
Prob not much of a contest.
|3 years 48 weeks ago
|Love 'em
Michigan's are great. Oregon's are great. Notre Dame's Soldier Field unis are awful.
|3 years 50 weeks ago
|Great news
We could need him if the Gardner experiment doesn't work or if injuries or other issues affect depth.
|3 years 50 weeks ago
|Penn State Starts practice soon right?
I thought I read that once practice starts, a player would have to sit out a year if he practices with the team but then leaves PSU.
I have no problem with BIG schools taking PSU players. Why shouldn't our conference keep our own guys? It will be painful if Redd runs all over a BIG team in the Rose Bowl this year. At least it won't be Michigan since we are Title game bound!!
|3 years 51 weeks ago
|No tickets for me!
How sad. Hopefully, I will have some by the end of next week!
|3 years 51 weeks ago
Well played, sir!
|3 years 51 weeks ago
|Denard will be...
#5 behind Matt Barkley, The Honey Badger, Robert Woods, and (darkhorse) Geno Smith of WVU. I am probably missing a dominating DL/OL but in terms of skill guys, Denard would likely not be far behind those guys.
|3 years 51 weeks ago
|Looks like Redd next
Sounds like he enjoyed his visit to USC. Also, I read that Bolden's name is no longer on PSU's online roster. I imagine between 5-10 players will leave when it's all said and done.
|4 years 4 days ago
|Don't see divisions changing
I think Wisc and Ohio and Michigan and Nebraska will be the top two contenders in each division.
|4 years 4 days ago
|Coaches Conference
Will be interesting to see how many questions are asked to coaches and players this week? Even though NCAA is moving fast to make this happen, the questions will go on all year and then, if there is a suspension, once the team returns to the field.
|4 years 6 days ago
|They are doing more?
I didn't know that. What's the plan for revamping? I love all things Batman. Very intrigued!
|4 years 1 week ago
I might have to rent it and check it out.
|4 years 1 week ago
|Is the passing mode as different as advertised?
Otherwise, I will stick with '12. Oh, and the scouting mode for recruiting? Helpful or overkill?
|4 years 1 week ago
|Graham Elliott - Chicago
Had some champagne and some wine. Hey, someone's gotta live up that Michigan "wine and cheese" crowd image!
|4 years 2 weeks ago
|First game of my senior year
I remember walking to the game and hearing people in the crowd saying they heard rumors that Gutierrez was hurt. Then, it was finally time for the offense to take the field. I heard all kinds of things in the stands.
"What happened to Gutierrez?" People pronouncing Henne as "Hen" and no one correcting them because no one knew! It was all confusion! Kid could play.
|4 years 2 weeks ago
|Very exciting
Beilein will find a way to integrate the freshman in so they can contribute. Need Burke to stay healthy. Think we could be okay with an injury to THJ or even Morgan but need Burke.
|4 years 13 weeks ago
|Didn't RR get some kid named...
Jake Ryan from outside of Cleveland? Saw him get into a couple games last year.
|4 years 13 weeks ago
|Great read
Thanks for posting! Hope the people who hated on Stu get a chance to read this so they can at least try to understand what he went through!
|4 years 13 weeks ago
|Reports emerging
that the Titanic has in fact struck an iceberg.
|4 years 13 weeks ago
Ishaq Williams (barring the ridiculous late hit; gold on gold crime!!)
All receivers not named Riddick
|4 years 13 weeks ago
|Tired of RR's S
or tired of fans talking about him?
Seems like a good guy and a good coach to me! Will support the Cats for sure second only to Michigan in my college football who to root for rankings!
|4 years 13 weeks ago
|Someone will pay for the band
Obviously, I can't guarantee this but I just have a feeling that someone will pay for the band to go. If I recall correctly, when OSU went to Texas or USC a few years ago, an anonymous donor stepped up to pay the band's costs.
I would hope that we have as generous a donor somewhere out there! Calling Stephen Ross!!
|4 years 20 weeks ago
|"They left him alone!"
My favorite call of the day. Love watching the highlights of this game.
|4 years 33 weeks ago
Here's why:
(1) Conference champions.
(2) OSU has defeated much better teams than Alabama. I believe 5 Top 25 wins for OSU and 2 for Alabama.
(3) No rematch. 2006!
(4) Would like to see Weeden-Blackmon against Claiborne/Matthieu (sp?).
|4 years 34 weeks ago
|Loved Sushi Town
Went there at least once a week during law school. Lived next door to it so very convenient!
|4 years 34 weeks ago
|My Top 5
Final Four
World Cup
Olympic 100m
|4 years 35 weeks ago
|It will be what it will be
Michigan will have a great coaching staff and recruit 25-28 highly-rated players per year. Ohio will have a great coaching staff and recruit 25-28 highly-rated players per year (okay, maybe 15-20 for a few years! HA!).
Both schools being great is just more fun for the fans. Another 1 vs. 2 game with the entire nation watching would be fabulous.
|4 years 35 weeks ago
|I would prefer the Fiesta Bowl
only so I do not have to take a day off of work to attend!
|4 years 35 weeks ago
|Beat Toledo!
It is apparently U of A's first game in 2012!
|4 years 35 weeks ago
|He should...
Remember to say "Bear Down Arizona" at least twice during his opening press conference.
Know the backstory of Bear Down Arizona.
Mention the names of a few players that the fans love.
Hire a defensive coordinator who is smart and that Rich will not want to micromanage.
Hire some assts with connections to CA and TX. He's got Florida covered by himself.
BEAT ASU. They should be going through a coaching change of their own so he should have a good shot in his first year.
Bond with EVERYONE in a leadership position at the University and attend numerous booster events.
Find the next Denard Robinson.
|4 years 35 weeks ago
This is great. Thanks for posting. He definitely needs a DC and I'm sure he knows it. I wonder whether Casteel is top of his list or if he would try to work with someone he had never had on staff before. I haven't heard whether Jon Tenuta or Randy Shannon ended up anywhere. Maybe he will reach out to them.
|4 years 35 weeks ago
|Go Rich Rod
I predict in his opening press conference he will predict that Rhett will be the future quarterback at Arizona. :-)
I hope he does great out there and that he can get U of A to the Rose Bowl!
|4 years 37 weeks ago
|LeSean "Shady" McCoy
What a move on that short little pass inside the 10. Totally set up the defender to get all air. This game is good.
|4 years 37 weeks ago
Arizona must have gotten out of trouble in a hurry. Up by 17 now...
|4 years 37 weeks ago
|Totally OT
But don't you mean Brabbs instead of Neinberg in your signature line?
|4 years 37 weeks ago
|Michigan wins big
Huge first quarter ends with M up 21-0. Borges never lets up. 49-17 when it's all said and done. You heard it here first!!!
|4 years 37 weeks ago
|It is at 330 est
It is on mgoblue.com under the schedule
|4 years 37 weeks ago
I am of the belief that Denard did not have as many progressions to go through last year. I think the spread passing game Rodriguez and Magee had implemented to that point was built on one to two reads that Denard had to make quickly whereas now Borges has the wide receivers running much more complex routes and which require Denard to wait and maybe make 4 to 5 reads.
I believe Rich made the game simple for him since he was just a first year starter. I also agree that he never scrambled last year either. There is one specific play that comes to mind. Against Illinois, he moved out of the pocket and had about 15-20 yards if he chose to run. Instead, he waited and found JR Hemingway for a play that ended up as a touchdown but I vividly remember screaming "RUN" at the tv.
|4 years 37 weeks ago
|I believe it will be
the winner of Nebraska/Iowa versus Wisconsin.
|4 years 37 weeks ago
|Missing something
You did not mention whether the new manager wears a headset (bluetooth) or just manages by coaching his staff and pointing.
|4 years 37 weeks ago
I fully expect the pain of this loss to be made even worse when an ESPN sidebar shows up on Tuesday that says "Big Ten Apologizes to Michigan for Incorrect Call"
|4 years 37 weeks ago
|Very troubling PI miss
but, still you win some, you lose some. Team has to recover from this by the time they get back from Iowa as they have a short week before traveling again to face another stingy defense on the road. Let's hope they can...
|4 years 37 weeks ago
Tigers 17, Tide 14. Tide miss last second field goal to tie.
|4 years 38 weeks ago
As with any kid, hope he can right the ship!
|4 years 38 weeks ago
|I'm going to go ahead
and say Wisconsin has a new special teams coach next year...
|4 years 38 weeks ago
|Was very confused
with Paterno's timeout use down there as well. Especially if he was only going to write Power 47 on a piece of paper...
|4 years 38 weeks ago
|Amazing Read
Thanks for posting. Sometimes we demand so much of them for a simple game that we (or maybe just myself) forget that they are human and are fighting many other battles other than football. His mom would be very proud of him.
Go Molk! Go Blue!
Also, Poor Jack Miller.
|4 years 39 weeks ago
|For lack of better analysis
signing him would be great. Who was the last big safety recruit who panned out, Shazor?
|4 years 39 weeks ago
|For lack of better analysis
signing him would be great. Who was the last big safety recruit who panned out, Shazor?
|4 years 39 weeks ago
|I feel like
Jeremy Foley, Florida's AD has been pretty outspoken about oversigning issue.
|4 years 39 weeks ago
|It would be best...
for the whole 10000+ lines of notes he made to get published. :-) I know I would pay a high price to buy it!
[Edit: Since I realized my response was kinda OT, I should add that errors like this happen all the time. I remember seeing some similar game history errors in Jon Falk's recent book too. Shocked that no one catches these, but I will guess that the reviewers don't spend all their time obsessing over M Football like I do! :-)]
|4 years 39 weeks ago
|Can't wait for hoops
Steady wing play can help overcome the troubles faced by freshmen point guards trying to make the adjustment to the college game. We will need some great point guard play, however, to make it through the Big Ten tournament and NCAA tournament. I have confidence our veterans can lead the way and help Trey and Carlton along until they learn enough to show some leadership of their own down the road.
I'm also intrigued to see what Bacari Alexander can do now that he's had time to work with Jon Horford. He did an amazing job with Jordan Morgan.
|4 years 39 weeks ago
|Even validation prices increasing
First year of undergrad, there was no need for validation. Then, $25-27 IIRC. Now, up to meet face! Crazy.
|4 years 39 weeks ago
|TV Contracts Changed Everything
Kids can go anywhere to get on television now rather than just the big schools. And as said above, NFL scouts are looking all over. I'm in my 20s but I have to believe if you wanted to get noticed in the past, you had to go to the bigger schools that were on tv or radio or at a minimum had a large press following like UM, ND, USC, Texas, and OU.


text:
The No. 28 ranked Alabama Crimson Tide opened its Southeastern Conference series at Arkansas with a 17-9 victory from Baum Stadium on Friday night. The Tide collected 15 hits in the game, while scoring the most runs ever against the Razorbacks, in 74 games of the all-time series.
Click here for the original story.
Welcome to SECTalk.com
|Welcome to SECTalk.com -- The Home of 6 Straight National Titles!
You are currently accessing our site as a guest which means you can't access all of our features such as social groups, sports betting, and many more. By joining our free community you will have access to all of these great features as well as to participating in our forums, contacting other members, and much more. Registration only takes a minute and SECTalk.com is absolutely free, so please join today!
If you have any problems registering or signing in, please contact us.
Latest Topics
Latest News
Top Bettors
Top High Fived
No. 28 Alabama Baseball Defeats Arkansas 17-9 to open SEC Series
Started by Tider27, Mar 21 2014 09:51 PM
Similar Topics
|Started By
|Last Post Info
to all the alabama fans
Started by auburngator, 15 Jul 2016 In: SEC Sports → SEC Football Talk
- Hot 32 replies
- 1,677 views
Baseball #ProRebs Update - 07.27
Started by GoldenRebel, 26 Jul 2016 In: The West → Ole Miss Sports → Ole Miss News
- 0 replies
- 121 views
Open Practice to Kick Off 2016 Fan Day
Started by TheRealBrave, 25 Jul 2016 In: The East → Georgia Sports → Georgia News
- 0 replies
- 63 views
Sain Named UT Baseball Volunteer Assistant Coach
Started by SECTalk.com, 22 Jul 2016 In: The East → Tennessee Sports → Tennessee News
- 0 replies
- 60 views
Baseball Players Named to All-Star Teams
Started by SECTalk.com, 20 Jul 2016 In: The West → LSU Sports → LSU News
- 0 replies
- 108 views


text:
Home is where your heart is, but it should also be a place where you restore your spirit each day - where neighbors are your friends and walking into a local business is like seeing family. LINK in West Seattle is just the place you will find this inspired community vibe.
Living at LINK means surrounding yourself with amazing views of the Northwest - the Cascades Mountains, Elliott Bay and the downtown skyline - while the building itself is infused with local flair and oozes the spirit of the West Side. Each design detail has been thoughtfully appointed, environmentally conscious and built for functionality.
Looking for the best of both worlds? LINK is a 10 minute bus-ride from the hustle of downtown Seattle; and a 5 minute walk to some of the coziest coffee shops, trendiest cocktail lounges and restaurants - as well as unique shopping opportunities. Please call for an appointment today.
Your email has been sent!
You can update your info and preferences with My Profile.
Turn by turn directions from any starting point to Link
If you lived here, how long would it take to get to work?


text:
Holy Blood, Holy Grail (Paperback)
Usually Ships in 1-5 Days
Is the traditional, accepted view of the life of Christ in some way incomplete?
Is it possible Christ did not die on the cross?
Is it possible Jesus was married, a father, and that his bloodline still exists?
Is it possible that parchments found in the South of France a century ago reveal one of the best-kept secrets of Christendom?
Is it possible that these parchments contain the very heart of the mystery of the Holy Grail?
According to the authors of this extraordinarily provocative, meticulously researched book, not only are these things possible they are probably true so revolutionary, so original, so convincing, that the most faithful Christians will be moved; here is the book that has sparked worldwide controversey.
"Enough to seriously challenge many traditional Christian beliefs, if not alter them."
"Los Angeles Times Book Review"
"Like "Chariots of the Gods?."..the plot has all the elements of an international thriller."
"From the Paperback edition.
About the Author
Michael Baigent (1948-2013) was a researcher and writer best known for his book "Holy Blood, Holy Grail", coauthored with Richard Leigh and Henry Lincoln. He appeared in many documentaries on the origins of Christianity, Freemasonry, and the Grail legends. He was the editor of "Freemasonry Today" from 2001 to 2011 and the author or coauthor of 14 books, including "The Jesus Papers", "The Dead Sea Scrolls Deception", and "The Messianic Legacy".
Richard Leigh was a novelist and short story writer born in New Jersey to a British father and an American mother. Leigh earned a BA from Tufts University, a master s degree from the University of Chicago, and a PhD from the State University of New York at Stony Brook. He died in 2007.
Henry Lincoln is a noted documentary filmmaker and author. He coauthored the bestselling "Holy Blood, Holy Grail" with Michael Baigent and Richard Leigh, as well as "The Messianic Legacy, Key to the Sacred Pattern", and "The Templars Secret Island". He lives in Rennes-le-Chateau, France.


text:
Super 8 Pocatello Id, Pocatello
- Free continental breakfast, free WiFi, and free parking
Main amenities
- 80 guestrooms
- 24-hour front desk
- Air conditioning
What's around
- Holt Arena (2.6 mi / 4.2 km)
- Idaho State University (2.9 mi / 4.6 km)
- Portneuf Medical Center (2.7 mi / 4.3 km)
- L.E. and Thelma E. Stephens Performing Arts Center (3.8 mi / 6.2 km)
- Pocatello Zoo (4.7 mi / 7.5 km)
For families
- Connecting/adjoining rooms available
- Television
- Cable TV service
- Free self parking
Super 8 Pocatello Id, Pocatello
Hotel Info: 020 3027 9803from £58
- Standard Room, 1 King Bed with Sofabed
- Standard Room, 1 Queen Bed
- Standard Room, 2 Queen Beds
- Standard Room, 1 King Bed
- Standard Room, 1 Queen Bed
- Standard Room, 2 Queen Beds
- Room, 2 Queen Beds
- Standard Room, 1 Queen Bed, Accessible
- Standard Room, 1 Queen Bed
- King Non Smoking
- Standard Room, 1 King Bed
- Room, Accessible
- Room, Accessible
- Economy Room, 1 Queen Bed
Also popular with travellers from the UK
At a glance
Key facts
Hotel size
- This hotel has 80 rooms
- Check-in time starts at 2 PM
- Check-out time is 11 AM
Required at check in
- Credit card or cash deposit required
- Government-issued photo ID required
Travelling with others
- Pets allowed
- Restrictions apply *
- Free WiFi in public areas
- Free WiFi in rooms
- Free self parking
- RV/bus/truck parking
Nearby Two Star Pocatello hotels
In the hotel
- Free continental breakfast daily
- Golfing nearby
- 24-hour front desk
In the room
- Air conditioning
- Cable TV channels
- Free WiFi
- Free local calls
- Connecting/adjoining rooms available
Top Pocatello hotels
Nearby hotels
Super 8 Pocatello Id, Pocatello's small print
Also known as
- Super 8 Pocatello Id Motel
- Super 8 Pocatello Id
- Super 8 Pocatello Id
- Super 8 Pocatello Id Motel
The property has connecting/adjoining rooms, which are subject to availability and can be requested by contacting the property using the number on the booking confirmation.
Pet-friendly rooms can be requested by contacting the property at the number on the booking confirmation.
We have included all charges provided to us by this hotel. However, charges can vary, for example, based on length of stay or the room you book.
Recent reviews
Excellent 4.0 /5 from 377 reviews
Stayed for 2 days, staff was very helpful and courteous, the room was comfortable, breakfast was filling and tasty, and we enjoyed our stay!
Solid hotel. I'd stay again.
Good location, clean room.
Very helpful reception, we checked in early, plus we had an upgrade. Good value. It would have been nice if there had been tables, chairs and parasols on the grass outside in the fresh air.
Needed more than two pillows
Is the description of this hotel not correct? Tell us


text:
CIA chief John Brennan said on Sunday he expects 28 classified pages of a U.S. congressional report into the Sept. 11, 2001 attacks on the United States to be published, absolving Saudi Arabia of any responsibility.
"I think the 28 pages will be published and I support their publication and everyone will see the evidence that the Saudi government had nothing to do with it," Brennan said in an interview with Saudi-owned Arabiya TV. His comments were dubbed into Arabic.
9/11 News Archive
Secret 9/11 Report's Publication To Absolve Saudi Arabia: CIA Chief
CIA chief John Brennan said on Sunday he expects 28 classified pages of a U.S. congressional report into the Sept. 11, 2001 attacks on the United States to be published, absolving Saudi Arabia of any responsibility.
Inside a Senator's Crusade to Release the Missing 28 Pages of the 9/11 Report
Former Florida senator Bob Graham caused a stir when he used the term "aggressive deception" to describe the FBI's treatment of 28 pages from a 2003 congressional inquiry into the 9/11 attacks.
The word choice was intentional, the co-chair of the investigation of the 9/11 terrorist attacks told The Daily Beast, because to Graham, what the FBI did was worse than the conventional Washington cover-up.
Declassified documents detail 9/11 commission's inquiry into Saudi Arabia
Investigators for the 9/11 commission would later describe the scene in Saudi Arabia as chilling.
They took seats in front of a former Saudi diplomat who, many on the commission's staff believed, had been a ringleader of a Saudi government spy network inside the US that gave support to at least two of the 9/11 hijackers in California in the year before the 2001 attacks.
At first, the witness, 32-year-old Fahad al-Thumairy, dressed in traditional white robes and headdress, answered the questions calmly, his hands folded in front of him. But when the interrogation became confrontational, he began to squirm, literally, pushing himself back and forth in the chair, folding and unfolding his arms, as he was pressed about his ties to two Saudi hijackers who had lived in southern California before 9/11.
The FBI Is Keeping 80,000 Secret Files on the Saudis and 9/11
The Obama administration may soon release 28 classified pages from a congressional investigation that allegedly links Saudis in the United States to the 9/11 attackers. A former Republican member of the 9/11 Commission alleged Thursday that there was "clear evidence" of support for the hijackers from Saudi officials.
But in Florida, a federal judge is weighing whether to declassify portions of some 80,000 classified pages that could reveal far more about the hijackers' Saudis connections and their activities in the weeks preceding the worst attack on U.S. soil.
CIA Director: Missing 9/11 Report Pages Contain 'Inaccurate' Information
CIA Director John Brennan on Sunday defended the government's decision to withhold 28 pages of the 9/11 Commission Report, telling NBC the classified pages contain "inaccurate" information that could be used to tie Saudi Arabia to the 9/11 terror attacks.
"This chapter was kept out because of concerns about sensitive methods [and] investigative actions," Brennan told "Meet The Press" host Chuck Todd, adding that at the time these findings were issued, in 2002, the investigation into 9/11 was still underway.
More Articles...
Page 2 of 103